Alogliptin fixed-dose combos move forward in Europe as filings accepted
04:20 EDT 21 Jun 2012 | SCRIP
Takeda's delayed plans for the European commercialisation of alogliptin have taken another step forward with the formal acceptance for review by the European Medicines Agency of marketing authorisation applications for two fixed-dose combinations of..
Original Article: Alogliptin fixed-dose combos move forward in Europe as filings accepted
More From BioPortfolio on "Alogliptin fixed-dose combos move forward in Europe as filings accepted"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
